Summary of TERLIVAZ® (terlipressin): the first FDA-approved treatment for HRS in adults with rapid reduction in kidney function

Description

The Summary of TERLIVAZ® (terlipressin): the first FDA-approved treatment for HRS in adults with rapid reduction in kidney function. TLM theater will highlight the importance of early recognition and current diagnosis and treatment recommendations for hepatorenal syndrome–acute kidney injury (HRS-AKI).

Industry Supporter: Mallinckrodt Pharmaceuticals